Loading...

Home
Stock
PIRS

PIRS News & Events

-

$

0.000

0.000(0.000%)1D

Overview Forecast Valuation Earnings News

Loading...

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Select market data provided by Financial Markets Infrastructure and Data|LSEG

Broker connection service provided by Connect to brokerage accounts for data and trading SnapTrade

Company

Home
Contact
About Us
News Release

Market

Market Analysis
Crypto
Market Movers
Stock Monitor
All US Stocks

Strategies

AI Stock Picker
Swing Trading
QuantAI Alpha Pick
CoinSwing
Daytrading Radar
Crypto Radar
Char Pattern Detection

Resource

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat with Tia
AI Screener
Backtesting Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Option Profit Calculator

Features

AI Stock Picker
Swing Trading
QuantAI Alpha Pick
Whales Auto Tracker
Daytrading Center
Patterns Detection
Financial AI Agent
AI Screener
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Stock Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Monitor News

Compare

TradingView
Seeking Alpha

PIRS News

Pieris Pharmaceuticals Announces Merger and Share Increase

Dec 12 2024Business Insider

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, ACNB, PIRS, OBDE on Behalf of Shareholders

Nov 21 2024PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYTH, BRKH, PIRS, CFB on Behalf of Shareholders

Nov 21 2024PRnewswire

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS

Nov 20 2024Businesswire

Pieris Pharmaceuticals: Q3 Earnings Snapshot

Nov 13 2024Yahoo Finance

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

Nov 07 2024Newsfilter

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

Oct 16 2024Globenewswire

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

Oct 15 2024Newsfilter

PIRS Events

Palvella Therapeutics apponts Matthew Korenberg as CFO

Palvella Therapeutics announced the appointment of Matthew Korenberg as CFO, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Korenberg joins Palvella from Ligand Pharmaceuticals Inc. (LGND), where he served as President and COO since 2022 and CFO from 2015 to 2022. In July 2024, Palvella and Pieris Pharmaceuticals, Inc. (PIRS) announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

PIRS Monitor News

an image of No data

No data

PIRS Earnings Analysis

an image of undefined

People Also Watch